Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), whic...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 397; no. 10290; pp. 2212 - 2224
Main Authors:	Powell, Elizabeth E, Wong, Vincent Wai-Sun, Rinella, Mary
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 05.06.2021 Elsevier B.V Elsevier Limited
Subjects:	Australia Biopsy Carcinoma, Hepatocellular - pathology Cardiovascular diseases Cirrhosis Developmental stages Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Disease Progression Drug approval Drug development Epidemiology Esophagus Fatty liver Fibrosis Gastrointestinal diseases Health aspects Health services Hepatitis Hepatocellular carcinoma Heterogeneity Humans Hypertension Inflammation Liver Liver cancer Liver cirrhosis Liver Cirrhosis - pathology Liver diseases Liver Neoplasms - pathology Malignancy Medical colleges Medical research Medicine, Experimental Metabolic disorders Metabolic syndrome Mortality Natural history Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - pathology Non-alcoholic Fatty Liver Disease - physiopathology Obesity Phenotypes Population Research institutes Risk factors Steatosis Transplants & implants Type 2 diabetes Weight reduction Australia United States > US
ISSN:	0140-6736, 1474-547X, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!